What Биосулин Н Treats: Main Uses and Benefits

Биосулин Н is commonly used in the long-term management of all forms of Diabetes Mellitus, including Type 1, Type 2, and Gestational Diabetes. It is applied in addressing the chronic, systemic issue of high blood glucose (hyperglycemia). Managing high blood sugar is part of a strategy that contributes to supporting long-term general well-being and helps ease symptoms linked to organ-specific functional stress.

This medicine is generally relevant in scenarios requiring consistent, basal (background) insulin replacement, which is applicable for managing symptoms related to systemic imbalance, such as excessive urination and thirst. A key benefit of using this intermediate-acting therapy is its role in supporting sustained glucose control over time, which contributes to easing the overall symptom load.

“This medication is considered relevant to help patients cope more steadily with symptom fluctuations by supporting fundamental, steady insulin supply.”

---

Quick Fact: Relief for Systemic Imbalance Биосулин Н is applied in addressing conditions where functional stability becomes affected, supporting the maintenance of stable blood sugar levels during rest and prolonged fasting periods.

Regulatory References

1. MedlinePlus Drug Information

Official Eligibility Rules for Биосулин Н

This section outlines who is eligible to use Биосулин Н (Insulin-isophane) and under what conditions, strictly according to government regulatory labeling.

Populations Contraindicated (Must Not Use)

Use of this medicine is absolutely contraindicated in patients who are experiencing an acute episode of hypoglycemia (low blood sugar). It is also prohibited for individuals with a documented hypersensitivity or allergy to human insulin (Insulin-isophane) or any other components within the formulation.

Target Populations and Age Groups

Биосулин Н is officially indicated for use in both adults and children who have been diagnosed with Diabetes Mellitus, including Type 1, Type 2, and Gestational Diabetes.

Populations Requiring Caution or Restriction

Specific population groups are permitted to use this medicine but require special caution and close clinical monitoring, as defined in official documents. This includes older adults (geriatric population) and patients with renal impairment (kidney disease) or hepatic impairment (liver disease), where dose adjustments may be necessary. Use during pregnancy and lactation is generally permitted, but necessitates careful and intensified blood glucose control.

The interaction profile for Биосулин Н (Insulin-isophane) is defined by officially documented pharmacodynamic effects, primarily involving agents that affect glucose regulation. These interactions are classified by regulatory authorities based on their formal impact on the medicine's blood glucose-lowering activity. The documented constraints focus on substances that either intensify or reduce the hypoglycemic effect.

Interactions Intensifying the Hypoglycemic Effect

Co-administration with certain medicinal products is formally documented to increase the risk of hypoglycemia. These agents include Oral Antidiabetic Agents, ACE Inhibitors, Monoamine Oxidase Inhibitors (MAOIs), and Salicylates. This effect is due to an additive action on glucose control, as noted in official prescribing information.

Interactions Reducing the Hypoglycemic Effect

Other classes of medicine are documented to counteract the blood glucose-lowering action of Биосулин Н. Substances that may lead to reduced efficacy include Corticosteroids, Diuretics (e.g., Thiazides), Thyroid Hormones, Sympathomimetics, and Atypical Antipsychotics. These interactions increase the risk of hyperglycemia, as described in government regulatory labels.

Other Documented Interactions

Alcohol is an officially documented substance that can unpredictably potentiate or inhibit the blood glucose-lowering action. Additionally, Beta-blockers are documented to mask the physiological signs of hypoglycemia, a critical constraint recorded in interaction sections. The risk of interaction-induced hypoglycemia may be increased in populations with existing renal or hepatic impairment.

Биосулин Н, an isophane suspension of human insulin, functions as an agonist at the Insulin Receptor (IR), a heterotetrameric transmembrane glycoprotein expressed on the surface of target cells, notably hepatocytes, adipocytes, and skeletal muscle cells

. The drug’s protracted action is due to its formulation as a neutral protamine Hagedorn (NPH) complex, which slowly dissolves after subcutaneous administration to release free insulin into systemic circulation.

Binding to the extracellular alpha-subunits of the IR activates the intrinsic tyrosine kinase activity of the intracellular beta-subunits. This triggers autophosphorylation and subsequent phosphorylation of intracellular substrates, primarily Insulin Receptor Substrate (IRS) proteins. Activation of the IRS proteins initiates several downstream signaling cascades, prominently the Phosphatidylinositol 3-Kinase (PI3K) / Akt (Protein Kinase B) pathway.

Within adipose and muscle tissues, the PI3K/Akt pathway mediates the translocation of Glucose Transporter type 4 (GLUT4) vesicles from the cytoplasm to the plasma membrane, enhancing the rate of glucose uptake from the blood. In the liver, this signaling cascade promotes glycogenesis and inhibits gluconeogenesis (glucose synthesis from non-carbohydrate precursors) and glycogenolysis (glycogen breakdown). System-level physiological modulation involves a net increase in glucose utilization and storage, and a reduction in hepatic glucose output, resulting in a systemic decrease in circulating glucose concentrations. Additionally, the drug promotes anabolism through the synthesis of lipids and proteins.

Official Administration Protocol for Биосулин Н

Биосулин Н (Insulin-isophane human, NPH) is an injectable suspension (100 units/mL) that is administered exclusively via subcutaneous injection (SC). This route is mandatory to ensure the intermediate-acting profile is maintained, and administration by the intravenous (IV) or intramuscular (IM) routes is prohibited. Furthermore, the suspension must not be used in an insulin infusion pump.

Preparation and Administration

Proper preparation is required before each injection. The suspension must be gently mixed (resuspended) immediately prior to use until it appears uniformly white and cloudy. This involves rolling the pen or vial between the hands and inverting it approximately 10 times. Vigorous shaking is forbidden as it can alter the formulation. The injection site must be rotated within the designated area (such as the abdomen or thigh) to ensure consistent absorption and maintain skin health.

Dosing and Frequency

Dosage is determined by individual metabolic requirements and is typically part of a long-term treatment plan requiring ongoing adjustment. While typical total daily insulin requirements generally fall between 0.5 to 1.0 Units/kg/day, the regimen is highly individualized. Биосулин Н is usually administered once or twice daily. When co-administered with a rapid or short-acting insulin, administration must occur within 15 minutes before or immediately after a meal.

Specific dose adjustment considerations, which may include a reduction, are often necessary for older adults and patients with hepatic or renal impairment.

Research evidence / Overview of studies for Биосулин Н

Evidence Supporting Use in Type 1 Diabetes

Research examined the role of this intermediate-acting human insulin isophane for basal insulin replacement in individuals with Type 1 Diabetes. Studies, including Randomized Controlled Trials (RCTs) and Systematic Reviews, tracked outcomes related to systemic or functional imbalance by measuring biomarkers like Glycated Hemoglobin (HbA1c) and Fasting Plasma Glucose (FPG). Findings describe patterns observed in the studies related to overall glucose management. Some trials also carefully monitored the frequency of low blood sugar events, specifically focusing on nocturnal hypoglycemia, when compared against different insulin formulations.

A key limitation is the absence of recent, extended-duration RCTs focused purely on long-term complication outcomes, such as cardiovascular events. Also, the physical appearance of the insulin, a cloudy suspension, can introduce differences in how trials are conducted compared to clear solutions, potentially influencing some findings.

Evidence Supporting Use in Type 2 Diabetes

Studies exploring the use of this basal insulin in adults with Type 2 Diabetes include both clinical trials examining different active treatments and Real-World Observational Studies. Research has focused on patients who required insulin when oral medications alone were insufficient, or who were already utilizing combination therapy. Studies tracked key measures of glycemic control, such as HbA1c and FPG.

Findings describe patterns related to glycemic parameters that were monitored in the observed populations during the study period. However, the certainty remains low because a substantial part of the evidence for insulin use in Type 2 Diabetes is derived from real-world settings, where results can be influenced by unmeasured variables and limit certainty. Furthermore, follow-up durations were limited in some comparative trials, meaning long-term effects are not fully established when directly comparing this specific product to other long-acting insulin preparations.

Studies on Therapeutic Profile and Bioequivalence

The fundamental research supporting this medicine involves specialized Pharmacokinetic (PK) and Pharmacodynamic (PD) studies. The research examined and described the intermediate-acting profile, including when the insulin action typically begins, reaches its peak action (highest concentration/glucose lowering), and ends.

Findings describe patterns observed in the studies that confirmed the biosynthetic molecule was studied for therapeutic equivalence to other established human NPH insulin preparations. The research describes patterns where the molecule’s action profile was observed as consistent with other human isophane insulins. Research provides context but not individual predictions regarding the exact timing of the peak action.

Key Studies & References

1. NPH Insulin - StatPearls - NCBI Bookshelf (Pharmacokinetics and Indications)

Common questions about Биосулин Н (FAQ)

Q: What does the 'Н' stand for in Биосулин Н?

The 'Н' in Биосулин Н refers to Neutral Protamine Hagedorn (NPH). This term describes the specific formulation of the product, which includes protamine and zinc to help slow down the absorption of the insulin, giving it its characteristic intermediate duration of action.

Q: How quickly does Биосулин Н start working?

Official information indicates that the typical onset of action for this type of intermediate-acting insulin (NPH) is observed to begin approximately 1 to 3 hours after subcutaneous administration. This gradual start is consistent with its role as a longer-lasting, basal insulin.

Q: How long can the effect of Биосулин Н last?

The total duration of action for this intermediate-acting insulin formulation is generally described in official product information as lasting up to 24 hours. Individual duration of effect may vary.

Q: How does the onset time of Биосулин Н compare to rapid-acting insulins?

The onset of action for Биосулин Н typically starts in 1 to 3 hours. This is a significantly slower starting time compared to rapid-acting insulin formulations, which begin to work much more quickly.

Q: Why is it described as an 'intermediate-acting' insulin?

Биосулин Н is classified as intermediate-acting because its composition includes stabilizing proteins, such as protamine and zinc. These components create a temporary reservoir at the injection site, which delays the release of insulin into the bloodstream, establishing the drug's sustained effect.

Q: Does Биосулин Н help control blood sugar primarily between meals?

Yes, as a basal insulin, the general purpose of Биосулин Н is to provide a continuous, low level of insulin. This is intended to help regulate blood sugar primarily between meals and overnight, supporting the body's baseline metabolic needs.

Q: Can individuals with kidney issues use Биосулин Н?

Official documents state that use is generally permitted for individuals with kidney impairment, but this population requires special caution and close clinical monitoring. The necessity of a dosage adjustment is often discussed, given that the kidneys play a role in insulin clearance.

Q: Can Биосулин Н be used in older adults?

Official documents allow its use in older adults. Official guidance emphasizes the need for special caution and closer clinical monitoring for this population, often involving dose adjustments.

Q: Does official prescribing information discuss the use of Биосулин Н in patients with liver problems?

Yes, official documents advise that patients with liver impairment require special caution. This is due to the potential for the liver's role in insulin metabolism to be affected, which may necessitate dosage adjustments to maintain appropriate blood sugar levels.

Q: Is there any difference between Биосулин Н and Neutral Protamine Hagedorn (NPH) insulin?

Биосулин Н is the specific name given to the drug product whose active ingredient is Insulin-isophane human. Insulin-isophane human is the official, pharmaceutical name for the class of intermediate-acting insulin commonly known as Neutral Protamine Hagedorn (NPH) insulin.

Q: Does alcohol change the way Биосулин Н works?

Official documents list alcohol as a substance that may interact with insulin products. Official documents describe alcohol as a substance that may unpredictably either intensify or reduce the blood sugar-lowering effect of the medicine.

Q: Can Биосулин Н be used by children?

Official labeling indicates that Биосулин Н (Insulin-isophane human) is formally indicated for use in both adults and pediatric patients who have been diagnosed with diabetes mellitus.

Q: Is there information about using Биосулин Н during pregnancy?

Official documents generally permit the use of this insulin during pregnancy and lactation. However, it is noted that careful and intensified blood glucose control is generally emphasized during these periods.

Q: Do many users report weight changes after starting Биосулин Н?

Official safety information for this class of medicine often lists weight gain as a common, documented adverse reaction. This is a known effect associated with insulin therapy in general.

Q: Is it common to experience skin reactions at the injection site with Биосулин Н?

Yes, local injection site reactions are documented in official safety information as common adverse reactions. These may include redness, pain, itching, or swelling at the spot where the injection was given.

Q: Do regulatory documents mention any specific types of food that interact with Биосулин Н?

Official dosage information notes that changes in meal patterns, such as significant changes to the content or timing of food intake, may necessitate dosage adjustments. Specific food-to-drug interactions are not typically listed, but changes in diet affect the necessary insulin dose.

Q: Is it true that certain blood pressure medicines can affect the activity of Биосулин Н?

Yes, official interaction documents list several types of blood pressure medications that can affect the activity of this insulin. For example, certain medicines may intensify the blood sugar-lowering effect, while others may reduce it.

Q: What are the general expectations for the effect of Биосулин Н?

Based on pharmacodynamic studies, the general expectation for this intermediate-acting insulin is a slow onset of action starting around 1–3 hours after injection. The effect typically reaches its highest activity between 4–8 hours and can last up to 24 hours.

Q: Is there research evidence available on the long-term use of Биосулин Н?

Research documents describe patterns observed from long-term clinical use and observational studies for this class of insulin. However, official summaries note a current limitation regarding recent, extended-duration randomized controlled trials focused purely on long-term complication outcomes, such as cardiovascular events.

Q: Is Биосулин Н available in a pen form?

Yes, official packaging information indicates that this medicine is supplied both in multi-use vials and in prefilled, single-patient-use pen devices for subcutaneous injection.

Q: What temperature is Биосулин Н usually stored at before opening?

Official storage guidelines require that unopened, unused medicine be refrigerated. It must be stored between 2 C to 8 C (36 F to 46 F) and kept in its original carton to protect it from light.

Q: Can Биосулин Н be mixed with other insulin products?

Official administration guidelines state that this medicine can be mixed in the same syringe with specific short-acting human insulin preparations. Official directions state that if a mixture is created, immediate administration is required after preparation.

Q: What happens if Биосулин Н is exposed to heat?

Official storage guidelines advise protection from direct heat, as extreme temperatures may damage the medicine and lead to a loss of effectiveness. The product must also be protected from freezing.

Q: Is there any research looking at Биосулин Н's use in combination with oral diabetes medicines?

Yes, official interaction documents and research have examined the use of this insulin in combination with oral anti-diabetic medications. This is often done, particularly in patients with Type 2 Diabetes who require additional insulin support for glucose management.

Q: Is it normal to feel tired when first starting Биосулин Н?

Official safety documents list unusual tiredness as a potential symptom of hypoglycemia (low blood sugar). Hypoglycemia is the most common adverse reaction associated with insulin use.

Q: Does the manufacturer of Биосулин Н provide patient education materials?

Yes, regulatory documents require that the manufacturer provide detailed Instructions for Use and Patient Information Leaflets alongside the medicine. These materials explain proper usage and storage.

Q: Is there a maximum number of injections per day typically described in use conditions?

Official use conditions typically describe administration as a once or twice daily regimen. The specific frequency and number of injections are determined based on individual metabolic needs.

Q: Does using Биосулин Н require any changes to diet?

Official dosage information notes that changes to meal patterns, including the type or timing of food intake, may require adjustments to the dosage of this medicine. Consistency in diet is often discussed in relation to insulin use.

Q: Is it described anywhere that people can develop a tolerance to Биосулин Н over time?

Official documents mention the observation of the development of antibodies that react with human insulin. This biological change may lead to insulin resistance, which would require changes to the dosage regimen.

Q: Does the package insert for Биосулин Н list any warnings related to driving?

Official safety warnings caution that hypoglycemia (low blood sugar), a primary risk of insulin use, can impair the ability to concentrate and react. Patients are cautioned that this effect can influence complex tasks such as driving.

Official Storage and Disposal Instructions

The storage requirements for Биосулин Н (Insulin-Isophane) are defined by specific regulatory constraints to ensure stability.

Product State	Temperature Requirement	Duration / Restriction
Unopened (Unused)	Refrigerate: 2 C to 8 C (36 F to 46 F)	Store in original carton; use until expiration date.
Opened (In-Use) Vials	Room Temperature: Below 30 C (86 F)	Discard after 31 days.
Opened (In-Use) Pens	Room Temperature: Below 30 C (86 F)	Discard after 14 to 28 days (product-specific).

All forms of the medicine must be protected from light and direct heat, and it is mandatory not to freeze the product. The medication must be kept out of the reach of children. Used needles and syringes must be discarded immediately into a designated, puncture-resistant sharps container. Unused or expired product should be disposed of in accordance with official local regulations.